Literature DB >> 15184946

Ocular-hypertensive response and corneal endothelial changes after intravitreal triamcinolone injections in Chinese subjects: a 6-month follow-up study.

C K M Chan1, D S P Fan, Wai-man Chan, W W Lai, V Y W Lee, D S C Lam.   

Abstract

PURPOSE: To assess the intraocular pressure (IOP) and corneal endothelial changes, over a 6-month period, after a single injection of intravitreal triamcinolone (ivTA) in Chinese patients.
METHODS: A total of 43 eyes of 43 consecutive Chinese patients with various macular diseases received a single bolus injection of 4 mg ivTA, of which, 14 eyes with significant cataracts underwent simultaneous phacoemulsification and primary intraocular lens implantation. IOP was measured preoperatively and weekly in the first month, and then monthly until 6 months postinjection. Specular microscopy was performed on 24 of the 29 eyes without simultaneous cataract surgery, preoperatively and at months 1, 3, and 6.
RESULTS: All patients completed 6 months of follow-up. Nine out of 43 (20.9%) eyes had IOP >21 mmHg. Their mean maximum IOP was 29.2 mmHg (range 23.0-37.0), necessitating the use of 2.0 types of topical antiglaucomatous medications on average. The IOP elevation occurred at a mean of 5.2 weeks (range 1-17) postinjection. All IOPs returned to normal, without additional antiglaucomatous medications, by 6 months. There was no statistically significant difference (paired t-test, P<0.05) in the corneal endothelial cell count and other specular microscopy parameters up to 6 months after the injections.
CONCLUSION: A single 4 mg bolus injection of ivTA appeared to have no harmful effects on the corneal endothelium. IvTA caused transient IOP elevations in 20.9% of Chinese patients, similar to that observed in Caucasians. As the IOP rise can occur as early as 1 week after the injection, early monitoring will help its early detection and prevent optic nerve damage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15184946     DOI: 10.1038/sj.eye.6701585

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  7 in total

1.  A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema.

Authors:  Dennis S C Lam; Carmen K M Chan; Shaheeda Mohamed; Timothy Y Y Lai; Kenneth K W Li; Patrick S H Li; Chi-Wai Tsang; Wai-Man Chan; Mahesh P Shanmugam
Journal:  Br J Ophthalmol       Date:  2006-09-14       Impact factor: 4.638

Review 2.  Management of sight-threatening uveitis: new therapeutic options.

Authors:  Matthias D Becker; Justine R Smith; Regina Max; Christoph Fiehn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections.

Authors:  A M Tammewar; L Cheng; O R Kayikcioglu; I A Falkenstein; I Kozak; M H Goldbaum; W R Freeman
Journal:  Br J Ophthalmol       Date:  2008-04-17       Impact factor: 4.638

4.  Pharmacokinetics and retinal toxicity of various doses of intravitreal triamcinolone acetonide in rabbits.

Authors:  You-Fan Ye; Yong-Feng Gao; Hua-Tao Xie; Hai-Jun Wang
Journal:  Mol Vis       Date:  2014-05-13       Impact factor: 2.367

5.  Novel Triamcinolone Acetonide-Loaded Liposomes Topical Formulation for the Treatment of Cystoid Macular Edema After Cataract Surgery: A Pilot Study.

Authors:  Alejandro Gonzalez-De la Rosa; Jose Navarro-Partida; Juan Carlos Altamirano-Vallejo; Ada Gabriela Hernandez-Gamez; Jesus Javier Garcia-Bañuelos; Juan Armendariz-Borunda; Arturo Santos
Journal:  J Ocul Pharmacol Ther       Date:  2019-01-07       Impact factor: 2.671

6.  Comparative Outcomes of Standard Perioperative Eye Drops, Intravitreal Triamcinolone Acetonide-Moxifloxacin, and Intracameral Dexamethasone-Moxifloxacin-Ketorolac in Cataract Surgery.

Authors:  Robin K Kuriakose; Soungmin Cho; Saman Nassiri; Frank S Hwang
Journal:  J Ophthalmol       Date:  2022-07-19       Impact factor: 1.974

7.  Safety and Tolerability of Topical Ophthalmic Triamcinolone Acetonide-Loaded Liposomes Formulation and Evaluation of Its Biologic Activity in Patients with Diabetic Macular Edema.

Authors:  Jose Navarro-Partida; Juan Carlos Altamirano-Vallejo; Alejandro Gonzalez-De la Rosa; Juan Armendariz-Borunda; Carlos Rodrigo Castro-Castaneda; Arturo Santos
Journal:  Pharmaceutics       Date:  2021-03-02       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.